These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 11072108)
21. Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes. Fei Q; Zhang H; Fu L; Dai X; Gao B; Ni M; Ge C; Li J; Ding X; Ke Y; Yao X; Zhu J Acta Biochim Biophys Sin (Shanghai); 2008 Jun; 40(6):466-77. PubMed ID: 18535745 [TBL] [Abstract][Full Text] [Related]
22. Non-viral delivery of ribozymes for cancer gene therapy. Kashani-Sabet M Expert Opin Biol Ther; 2004 Nov; 4(11):1749-55. PubMed ID: 15500403 [TBL] [Abstract][Full Text] [Related]
23. Ribozymes. Their functions and strategies for their use. Gibson SA; Shillitoe EJ Mol Biotechnol; 1997 Apr; 7(2):125-37. PubMed ID: 9219227 [TBL] [Abstract][Full Text] [Related]
28. Ribozymes: recent advances in the development of RNA tools. Puerta-Fernández E; Romero-López C; Barroso-delJesus A; Berzal-Herranz A FEMS Microbiol Rev; 2003 Apr; 27(1):75-97. PubMed ID: 12697343 [TBL] [Abstract][Full Text] [Related]
29. A Discovery with Potential to Revitalize Hammerhead Ribozyme Therapeutics for Treatment of Inherited Retinal Degenerations. Trujillo AJ; Myers JM; Fayazi ZS; Butler MC; Sullivan JM Adv Exp Med Biol; 2019; 1185():119-124. PubMed ID: 31884599 [TBL] [Abstract][Full Text] [Related]
30. Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. Tanaka K; Yamada T; Ohyagi Y; Asahara H; Horiuchi I; Kira J J Neurol Sci; 2001 Jan; 183(1):79-84. PubMed ID: 11166799 [TBL] [Abstract][Full Text] [Related]
31. Ribozymes in gene therapy of HIV-1. Macpherson JL; Ely JA; Sun LQ; Symonds GP Front Biosci; 1999 Jun; 4():D497-505. PubMed ID: 10352136 [TBL] [Abstract][Full Text] [Related]
32. Ribozymes: from mechanistic studies to applications in vivo. Ohkawa J; Koguma T; Kohda T; Taira K J Biochem; 1995 Aug; 118(2):251-8. PubMed ID: 8543555 [TBL] [Abstract][Full Text] [Related]
33. Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast. Castanotto D; Li H; Chow W; Rossi JJ; Deshler JO Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):1-13. PubMed ID: 9512091 [TBL] [Abstract][Full Text] [Related]
34. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents. Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650 [TBL] [Abstract][Full Text] [Related]
35. Catalytic DNA: a novel tool for gene suppression. Cairns MJ; Saravolac EG; Sun LQ Curr Drug Targets; 2002 Jun; 3(3):269-79. PubMed ID: 12041740 [TBL] [Abstract][Full Text] [Related]
36. The potential application of ribozymes for the treatment of hematological disorders. James HA J Leukoc Biol; 1999 Sep; 66(3):361-8. PubMed ID: 10496304 [TBL] [Abstract][Full Text] [Related]
37. Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific hammerhead ribozyme in vitro. Ohkawa K; Yuki N; Kanazawa Y; Ueda K; Mita E; Sasaki Y; Kasahara A; Hayashi N J Hepatol; 1997 Jul; 27(1):78-84. PubMed ID: 9252077 [TBL] [Abstract][Full Text] [Related]
38. The application of ribozymes and DNAzymes in muscle and brain. Mastroyiannopoulos NP; Uney JB; Phylactou LA Molecules; 2010 Aug; 15(8):5460-72. PubMed ID: 20714308 [TBL] [Abstract][Full Text] [Related]
39. Ribozyme- and deoxyribozyme-strategies for medical applications. Schubert S; Kurreck J Curr Drug Targets; 2004 Nov; 5(8):667-81. PubMed ID: 15578948 [TBL] [Abstract][Full Text] [Related]
40. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Yokoyama Y; Takahashi Y; Shinohara A; Wan X; Takahashi S; Niwa K; Tamaya T Biochem Biophys Res Commun; 2000 Jun; 273(1):316-21. PubMed ID: 10873604 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]